An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells.
Hepatocellular carcinoma (HCC) is characterized by alterations in multiple genes. High expression of CD147 on the surface of HCC cells promotes proliferation. The monoclonal antibody HAb18 recognizes CD147. We constructed an oncolytic adenoviral vector to express HAb18 (ZD55-HAb18) in HCC cells. Interleukin 24 (IL24) was co-expressed through the use of an F2A linker. ZD55-HAb18-IL24 decreased HCC cell viability to a greater degree than either ZD55-HAb18 or ZD55-IL24 alone. ZD55-HAb18-IL24 also induced apoptosis and autophagy in PLC/PRF/5 HCC cells. Intratumoral injection of ZD55-HAb18-IL24 repressed tumor growth in a PLC/PRF/5 xenograft model. Our results suggest that antibody-antitumor gene conjugation elicited a stronger antitumor effect than the antibody alone, and that this strategy could broaden the applications of antibody-based therapies in HCC.
['Yuan|Sujing|S|', 'Fang|Xianlong|X|', 'Xu|Yanni|Y|', 'Ni|Aimin|A|', 'Liu|Xin-Yuan|XY|', 'Chu|Liang|L|']
D000256:Adenoviridae D000911:Antibodies, Monoclonal D017209:Apoptosis D001343:Autophagy D051926:Basigin D006528:Carcinoma, Hepatocellular D005822:Genetic Vectors D006801:Humans D007167:Immunotherapy D007378:Interleukins D008113:Liver Neoplasms D050130:Oncolytic Virotherapy D014407:Tumor Cells, Cultured D019444:Vaccines, DNA
oncolytic adenovirus HAb18 interleukin 24 hepatocellular carcinoma CD147